Class summary at a glance.

Every drug in the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $512407combined across class
Total Rx claims: 390215 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Remdesivir

Brand: Veklury · 390 Part D claims (CY24) · 215 beneficiaries · First FDA approval: 2020-11-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $512407

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.